Management

Steven R. Miller, PhD, is responsible for Catalyst's product development program, which includes all aspects of chemistry and manufacturing controls, quality systems, contract operations, and development planning. He was responsible for identifying and in-licensing CPP-115, Catalyst's newest drug candidate, and in taking that product through an initial series of successful non-clinical studies. Dr. Miller has 25 years of experience in the pharmaceutical and healthcare industry. He served as Executive Director for Research and Development Operations for Watson Pharmaceuticals and previously as Vice President of Research and Product Development of Royce Laboratories. Dr. Miller also managed medical device development groups at Baxter Diagnostics and worked as an analytical chemist for the U.S. Food and Drug Administration. Dr. Miller received his doctorate in synthetic organic chemistry at the University of Miami, and his work has been published in numerous technical and professional journals including Journal of Analytical Chemistry, Journal of the American Chemical Society, and Chemical Communications.

Patrick J. McEnany has been Chief Executive Officer and a director of Catalyst since its formation in January 2002. In July 2006 he became Chairman, President and Chief Executive Officer. From 1991 to April of 1997, Mr. McEnany was Chairman and Chief Executive Officer of Royce Laboratories, Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. From 1993 through 1997, he also served as Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers. He currently serves on the Board of Directors for ThermoGenesis Corp., Renal CarePartners, Inc. and the Jackson Memorial Hospital Foundation.

Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm's Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.

M. Douglas Winship joined Catalyst in July 2006 as Vice President, Regulatory Operations. Mr. Winship has worked in regulatory affairs and clinical operations in the healthcare industry for more than 35 years. From 2004 to 2005, Mr. Winship was Vice President–Quality Assurance and Regulatory Affairs for Argos Therapeutics, Inc., a biotechnology company developing immunotherapy treatments for cancer, in Durham, North Carolina. Previously, Mr. Winship was employed by CEL-SCI Corp., a biotechnology company developing immune system based treatments, in Vienna, Virginia, from 1998 to 2002 as Senior Vice President–Regulatory Affairs and Quality Assurance, and from 1994 through 1998 as Vice President–Regulatory Affairs and Quality Assurance. From 1988 to 1994, Mr. Winship was employed by Curative Technologies, Inc. (now Wound Care Centers, Inc.), a health-care company involved in the wound-healing market, first as Director of Regulatory Affairs and Quality Assurance and later as Vice President of Regulatory Affairs and Quality Assurance. Mr. Winship earned his bachelor of science degree in chemistry from Upsala College in 1971.

Richard P. Rieger joined Catalyst in November 2011 as Vice President, Commercial Operations. He has more than 15 years of experience in the pharma­ceu­ti­cal and biotech industries, including franchise development and licensing/M&A in the central nervous system (CNS) area. He joined Catalyst from PhaseRx, Inc., where he served as Vice President, Business Development, and led their commercial initiatives. As a Senior Engagement Manager in L.E.K. Consulting's Life Sciences & Medical Technology practice, Mr. Rieger led more than 50 strategic engagements involving licensing/M&A, commercial planning, and portfolio development, and was responsible for corporate strategy and commercial support for CNS clients. Mr. Rieger also served as Vice President, Business Development, at Dendreon Corporation and held positions of increasing responsibility in business development and marketing at Abbott Laboratories, including CNS transactions and franchises. Mr. Rieger earned an MBA in finance and business policy with honors from the University of Chicago Booth School of Business and a bachelor of science degree in electrical engineering from the University of Notre Dame.

Charles W. Gorodetzky, MD, PhD, brings more than 40 years of knowledge and experience in pharmacology, drug development, clinical trials and addiction medicine to his work with Catalyst. During 21 years at the National Institute on Drug Abuse (NIDA) Addiction Research Center (ARC), Dr. Gorodetzky established and directed the Drug Me­tab­o­lism and Kinetics Section, publishing approximately 100 papers, as author or co-author, in urine-screening methodology and interpretation, drug metabolism and the human pharmacology of drug abuse. Dr. Gorodetzky has served on numerous committees and boards including the FDA's Drug Abuse Advisory Committee, the Veteran's Administration Subcommittee on Alcoholism and Drug Dependence of the Mental Health and Behavioral Sciences Program Committee, and the Special Action Office for Drug Abuse Prevention. Dr. Gorodetzky has been directly involved in the clinical development of vigabatrin since 1995. Dr. Gorodetzky left NIDA and joined the pharmaceutical industry in 1984 and worked for the next 21 years in clinical development, holding positions at Bur­roughs Well­come, Ciba Geigy, Cygnus Therapeutic Systems, and Hoechst Marion Roussel (HMR, now Sanofi Aventis). In 2005, he retired from Quintiles, Inc., where he was a vice president in the Medical and Scientific Services Department. Dr. Gorodetzky has been directly involved in the clinical development of vi­ga­ba­trin since 1995, initially as the primary responsible development person at HMR and then as the primary development person at Quintiles working with HMR in the clinical development of vigabatrin. For the past several years, as a clinical professor of psychiatry at the University of Missouri–Kansas City, Dr. Gorodetzky has participated as a co-principal in­ves­ti­ga­tor in the NIDA meth­am­phet­a­mine Clinical Trials Group. After obtaining his bachelor of science degree at MIT in 1958, he earned his medical degree at Boston University School of Medicine in 1962 and a doctor of philosophy degree in pharmacology from the University of Kentucky Medical Center in 1975.